3 sources
Jan 21
Giant-Cell Arteritis Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | AbbVie, Novartis, CSL, Kiniksa Pharma, Eli Lilly, Roche, Johnson & Johnson, MorphoSys AG
3 sources
Jan 21
Charcot Marie Tooth Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pharnext SA, MedDay Pharma, HELIXMITH, ENCell, Chong Kun Dang Pharm